![](https://investorshub.advfn.com/uicon/522650.png?cb=1464431304)
Wednesday, March 03, 2021 9:21:50 AM
Our technology works on all the products that affect the brain function especially the pleasure area even works on alcohol, okay.
Let's be clear about what naltrexone can and cannot do. Naltrexone is strong inhibitor of opioid receptors, especially mu receptors. It has a stronger affinity with the receptor than opioid molecules, so it blocks all available receptors and replaces any opioid that is already bound, which induces immediate opioid withdrawal. This is why it can be used in the 2 bead system as a "pharmacologic" ADF. Naltrexone is not a receptor inhibitor for any other classes of drugs, and so it *cannot* be used in a 2 bead ADF for any other class drugs. But naltrexone does have other uses. I have had very good luck prescribing it for alcohol use disorder. An alcoholic user takes it every day, and they report significantly decreased cravings to drink alcohol. It is also approved as a maintenance drug for opioid use disorder, but it has never proven effective for this because opioid addicts tend to not take it. Naltrexone is also a part of a combination drug with bupropion ("Wellbutrin," "Xyban") for obesity called Contrave. It is unclear how those drugs work together, but the theory is they somehow regulate appetite through dopamine pleasure/reward pathways.
In the last SequestOx trial, the company also ran a new non-pharmacologic ADF oxycodone formulation. The new formulation was described as a "physical" ADF, meaning it is a hard-shell that resists crushing and cannot be hydrated for a syringe. These are PEG-based formulations that do not contain naltrexone. This kind of hard-shell ADF could be used to make an ADF version of Adderall or any other CNS stimulant.
Nasrat is correct to say Elite's *hard-shell* physical ADF technology can be used for CNS stimulants, but it would be incorrect to say the naltrexone 2 bead pharmacologic ADF can be used for CNS stimulants. When he refers to "pleasure area" and "even works on alcohol," I assume he is referring to naltrexone. The hard-shell ADF has no effect on the pleasure centers in the brain, and it certainly cannot be used for alcohol. IMO, Nasrat was just plain old confused in the last call. He was mixing up the hard-shell physical ADF, which can be used with Adderall, and naltrexone 2 bead pharmacologic ADF, which cannot be used with Adderall. The result was gibberish nonsense, which is now being replicated as gospel. Ignorance is bliss, so they say.
Occam's razor: the simplest solution is most likely the right one.
Hanlon's razor: never attribute to malice that which is adequately explained by stupidity.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM